Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2018 Jun 12;9:1320. doi: 10.3389/fimmu.2018.01320

Natural Autoantibodies: An Undersugn Hero of the Immune System and Autoimmune Disorders—A Point of View

Stratis Avrameas 1, Haris Alexopoulos 2,*, Harry M Moutsopoulos 2,3
PMCID: PMC6005843  PMID: 29946320

Natural autoantibodies/natural autoimmunity forms a network that serves to protect the organism from outer and inner danger but may also contribute to autoimmune disease. This vital component of the immune system deserves, we think, much greater attention than it currently attracts. A better understanding of how natural autoimmunity contributes in the function of the immune system is needed and how the expansion of this process leads to autoimmune disorders is an intriguing question which we will address in this article.

Since the early days of immunology, pioneering work by Landsteiner and his group on haptens showed that immunization is a process that can raise highly specific antibodies. In the same era, Ehrlich put forward the dogma of “horror autotoxicus,” proclaiming the inability of the immune system to recognize self-constituents. Later on, in the 1950s, Burnet builds upon these seminal observations and formulated the clonal selection theory, which states that “cell clones produce highly specific antibodies for environmental constituents while the immune system is educated during ontogeny not to recognize self-constituents.”

Nevertheless, other studies, contradicting the “dogma,” were mostly ignored. These studies showed that circulating antibodies in normal human sera could recognize various substances, including self-antigens, albeit with a low avidity (1, 2). In the following years, additional experiments reinforced the notion of a persistent immune system reactivity against self, e.g., in normal mice (3, 4).

Many of these studies were neglected because the scientific community had adopted the “dogma” of clonal selection theory. Despite this opposition, “heretical” studies kept coming and demonstrated that autoreactive B-cells and polyreactive antibodies are abundant and actively participate in physiological immunity (5). In mice, innate-like B1 cells form a pool of long-lived population, which are positively selected for self reactivity and produce the majority of natural IgM antibodies. These antibodies protect against infection and are implicated in the gut microbiota homeostasis (6).

The Role of Polyreactivity in Natural Defenses

One of the main and consistent findings of these “heretical” studies we mentioned was that despite the undisputed distinction in the functions of B and T cells, both express a common feature that appears to be preserved during the evolutionary process; auto-polyreactivity (7, 8). In invertebrates and lower vertebrates, recognition of self-antigens is suggestive of an evolutionary process where multicellular organisms, probably in order to protect themselves from ominous invaders, began to produce both B- and T-cell receptors recognizing environmental constituents, derived from proteins employed in their embryonic development. In order to be able to recognize environmental constituents, they had to lose part of their ability to recognize self. In the course of evolution, these auto-polyreactive immune receptors ended up recognizing more avidly the external rather than the internal constituents of the organism (9). Higher vertebrates maintained the ability to produce these auto-polyreactive immune receptors. Since then, vertebrates acquired the additional capacity to produce specific receptors that recognize environmental antigens, yet, their ability to recognize self-antigens, via polyreactivity was maintained; an evolutionary genetic fossil maintained in the germline (10, 11). Is this ancient aspect of the immune system still relevant for day-to-day immunity? This network of low-specificity polyreactive natural antibodies is still crucial for instantly recognizing an acute infection and marking the invader for the first responders of the innate immunity. Their ability to bind both self and non-self molecules allows the binding of, e.g., cytokines and other self constituents, masking them from the adaptive immune system and, therefore, actively inhibiting pathogenic autoimmunity (12).

Under physiological conditions, auto-polyreactive immune receptors have their active site blocked by the high amount of available self-antigens. Auto-polyreactive immune receptors upon binding to self-antigens form immune complexes, which are subsequently eliminated from the circulation, primarily by phagocytosis (13). Auto-polyreactivity endows the immune system with the readily available capacity to recognize and interact with self and environment constituents, e.g., the gut microbiota, reminiscent of our ancestors (14). A vast network is created, which is changing perpetually depending upon the stimuli derived either from the internal or the external milieu of the organism contributing significantly to immune homeostasis. In disease states, where self-antigens are released, this network is a guardian that rapidly sequesters the self-antigens, e.g., in pathologic conditions such as demyelination, stroke, or pulmonary disease (1517). Also, vital homeostatic biological activities such as cellular repairing and enzymatic catalysis are also monitored by several auto-polyreactive immune receptors (7, 18). These data clearly demonstrate that reactivity against self exists and that it has a well-defined physiological role.

But What about Autoimmune Diseases?

The cardinal feature of an autoimmune disease is the unfolding of an excessive self-reactive, antigen-driven, immune response. The emergence of these disorders is considered a multifactorial process. Genetic predisposition (19, 20), environmental insults such as infections, chemical and physical agents (21), as well as stressful life events (22) all have been implicated. This self-addressed intense immune response is mediated by the physiological cytokine and immune cells repertoire and leads to organ dysfunction, hyperfunction, or tissue injury (23, 24). Are B- or T-cells that express natural autoantibody receptors the key links between natural self-polyreactivity and pathologic autoimmunity? To put it in other words, is there any evidence that excessive polyreactivity (including self-reactivity) can lead to disease? We propose that chronic activation of the immune system (25, 26) can lead to expansion of naturally present auto-polyreactive clones and, in genetically predisposed individuals, this can lead to the development of autoimmune disease. Our proposal is supported from clinical observations and experimental data.

It is well known that in sympathetic ophthalmia, release of hidden autoantigens in abundance, from, e.g., trauma of one eye are readily recognized by circulating preexisting autoreactive lymphocytic clones leading to autoimmune insult in the other eye (27). It is also well understood that chronic activation of the immune system, as occurs in chronic infections like subacute bacterial endocarditis (28), leishmaniosis (29), and others, may lead, in genetically susceptible individuals, to immune complex formation and development of autoimmune disease. Furthermore, many years ago, we have shown, followed by others that chronic activation of the immune system, as occurs in individuals who received allogeneic bone transplants and develop chronic graft versus host disease also leads to the development of a variety of systemic autoimmune diseases such as systemic lupus erythematosus (SLE), Sjögren’s syndrome, biliary cirrhosis, and scleroderma (3032).

Another important clue comes from the newly described age-associated B cells, which progressively accumulate with age. The appearance of these cells is correlated with disease onset in several murine SLE models (33). These cells are driven by a T-bet centered transcriptional program and progressively accumulate throughout life. These cells may well represent polyreactive memory B-cells, which recognize chronic pathogenic microbes but also autoantigens. The relative abundance of these cells in aging individuals may be an explanation of why autoimmune reactivity is more common in the elderly (34). This notion has also been demonstrated previously, in studies where, in healthy elderly individuals, a high incidence of autoantibodies was observed, particularly of the IgG isotype (35, 36). It would be worth investigating further the spectrum of autoantibodies in the elderly and whether these are produced by the age-associated B cells.

Further proof is arising from studying pathogenetic aspects of Sjögren’s syndrome, an autoimmune epithelitis (37). It is known, from studies in our and other laboratories, that the key player who initiates and perpetuates the autoimmune reactivity is the activated epithelium of the affected organs. We, and others, have shown that in patients with Sjögren’s syndrome, aggressive lymphocytic infiltrates surround the epithelia of the affected organs such as the salivary glands, the bronchi, the renal tubules, and the cholangia. Epithelia from labial minor salivary glands remain activated, even in long-term cultures, since they retain inappropriate expression of immune-regulatory molecules such as B7, ICAM, CD40, lympho-attractant chemokines, and pro-inflammatory cytokines, die from apoptotic death and release exosomes. Both apoptotic blebs and exosomes contain abundance of the autoantigens Ro and La, which in tandem with the activated epithelium, chronically activate the immune system rendering it aggressively autoreactive. As a result, the already present natural autoreactive lymphocytic clones may expand leading to the destruction of the affected organ and the development of autoimmune epithelitis. The question why the salivary gland epithelium of patients with Sjögren’s syndrome is activated is a fundamental and intriguing question. Our studies have shown that coxsackie viral sequences are present in the salivary gland epithelium of patients with Sjögren’s syndrome. Further studies are needed, however, to explore the exact etiopathogenetic role of this finding. All the aforementioned findings are reviewed in detail (38).

Conclusion

High avidity recognition, lack of specificity, and tolerance to self has been the dominant idea of the clonal selection theory that guided the thinking in immunology and autoimmunity. Nevertheless, results from both older and newer studies have established that the immune system can recognize self, principally through auto-polyreactive receptors. Only a minor part of the immune system expresses high specificity, while its largest part exhibits polyspecificity or otherwise polyreactivity. In genetically prone individuals, chronic immune activation may lead to expansion of autoreactive lymphocytic clones that can induce cell or organ damage and thus development of autoimmune disorders.

Author Contributions

SA, HA, and HM: drafting, editing, and final approval of manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer JW and the handling Editor declared their shared University affiliation although working in different departments.

References

  • 1.Landsteiner K. The Nature and Specificity of Antibodies. The Specificity of Serological Reactions. Boston: Harvard University Press; (1945). p. 127–55. [Google Scholar]
  • 2.Boyden SV. Natural antibodies and the immune response. Adv Immunol (1965) 5:1–28. 10.1016/S0065-2776(08)60271-0 [DOI] [PubMed] [Google Scholar]
  • 3.Dresser DW. Most IgM-producing cells in the mouse secrete auto-antibodies (rheumatoid factor). Nature (1978) 274:480–3. 10.1038/274480a0 [DOI] [PubMed] [Google Scholar]
  • 4.Steele EJ, Cunningham AJ. High proportion of Ig-producing cells making autoantibody in normal mice. Nature (1978) 274:483–4. 10.1038/274483a0 [DOI] [PubMed] [Google Scholar]
  • 5.Avrameas S, Ternynck T, Tsonis IA, Lymberi P. Naturally occurring B-cell autoreactivity: a critical overview. J Autoimmun (2007) 29:213–8. 10.1016/j.jaut.2007.07.010 [DOI] [PubMed] [Google Scholar]
  • 6.Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol (2011) 11:34–46. 10.1038/nri2901 [DOI] [PubMed] [Google Scholar]
  • 7.Avrameas S. Autopolyreactivity confers a holistic role in the immune system. Scand J Immunol (2016) 83:227–34. 10.1111/sji.12414 [DOI] [PubMed] [Google Scholar]
  • 8.Zhou ZH, Tzioufas AG, Notkins AL. Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J Autoimmun (2007) 29:219–28. 10.1016/j.jaut.2007.07.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lee W, Gaca JG, Edwards LA, Braedehoeft SJ, Parker W, Davis RD. Binding of polyreactive antibodies to self versus foreign antigens. Immunobiology (2002) 205:95–107. 10.1078/0171-2985-00113 [DOI] [PubMed] [Google Scholar]
  • 10.Baccala R, Quang TV, Gilbert M, Ternynck T, Avrameas S. Two murine natural polyreactive autoantibodies are encoded by nonmutated germ-line genes. Proc Natl Acad Sci U S A (1989) 86:4624–8. 10.1073/pnas.86.12.4624 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ikematsu H, Kasaian MT, Schettino EW, Casali P. Structural analysis of the VH-D-JH segments of human polyreactive IgG mAb. Evidence for somatic selection. J Immunol (1993) 151:3604–16. [PMC free article] [PubMed] [Google Scholar]
  • 12.Watanabe M, Uchida K, Nakagaki K, Trapnell BC, Nakata K. High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms. Cytokine Growth Factor Rev (2010) 21:263–73. 10.1016/j.cytogfr.2010.03.003 [DOI] [PubMed] [Google Scholar]
  • 13.Chen Y, Park YB, Patel E, Silverman GJ. IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J Immunol (2009) 182:6031–43. 10.4049/jimmunol.0804191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Christmann BS, Abrahamsson TR, Bernstein CN, Duck LW, Mannon PJ, Berg G, et al. Human seroreactivity to gut microbiota antigens. J Allergy Clin Immunol (2015) 136:1378–86.e1–5. 10.1016/j.jaci.2015.03.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Watzlawik JO, Wootla B, Painter MM, Warrington AE, Rodriguez M. Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire. Expert Rev Neurother (2013) 13:1017–29. 10.1586/14737175.2013.835601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Elvington A, Atkinson C, Kulik L, Zhu H, Yu J, Kindy MS, et al. Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol (2012) 188:1460–8. 10.4049/jimmunol.1102132 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Daffa NI, Tighe PJ, Corne JM, Fairclough LC, Todd I. Natural and disease-specific autoantibodies in chronic obstructive pulmonary disease. Clin Exp Immunol (2015) 180:155–63. 10.1111/cei.12565 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wright BR, Warrington AE, Edberg DD, Rodriguez M. Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies. Arch Neurol (2009) 66:1456–9. 10.1001/archneurol.2009.262 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.David T, Ling SF, Barton A. Genetics of immune-mediated inflammatory diseases. Clin Exp Immunol (2018). 10.1111/cei.13101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Thorsby E, Lie BA. HLA associated genetic predisposition to autoimmune diseases: genes involved and possible mechanisms. Transpl Immunol (2005) 14:175–82. 10.1016/j.trim.2005.03.021 [DOI] [PubMed] [Google Scholar]
  • 21.Shukla SK, Singh G, Ahmad S, Pant P. Infections, genetic and environmental factors in pathogenesis of autoimmune thyroid diseases. Microb Pathog (2018) 116:279–88. 10.1016/j.micpath.2018.01.004 [DOI] [PubMed] [Google Scholar]
  • 22.Skopouli FN, Katsiougiannis S. How stress contributes to autoimmunity-lessons from Sjogren’s syndrome. FEBS Lett (2018) 592:5–14. 10.1002/1873-3468.12933 [DOI] [PubMed] [Google Scholar]
  • 23.Tsonis IA, Avrameas S, Moutsopoulos HM. Autoimmunity and pathophysiology. J Autoimmun (2007) 29:203–5. 10.1016/j.jaut.2007.07.009 [DOI] [PubMed] [Google Scholar]
  • 24.Rose NR, Mackay IR. Autoimmune disease: the consequence of disturbed homeostasis. In: Ian R, Mackay NRR, editors. The Autoimmune Diseases. London: Elsevier; (2014). p. 3–9. [Google Scholar]
  • 25.Moutsopoulos HM, Boehm-Truitt M, Kassan SS, Chused TM. Demonstration of activation of B lymphocytes in New Zealand black mice at birth by an immunoradiometric assay for murine IgM. J Immunol (1977) 119:1639–44. [PubMed] [Google Scholar]
  • 26.Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol (2001) 2:764–6. 10.1038/ni0901-764 [DOI] [PubMed] [Google Scholar]
  • 27.Margo CE, Harman LE. Autoimmune disease: conceptual history and contributions of ocular immunology. Surv Ophthalmol (2016) 61:680–8. 10.1016/j.survophthal.2016.04.006 [DOI] [PubMed] [Google Scholar]
  • 28.Maisch B. Autoreactive mechanisms in infective endocarditis. Springer Semin Immunopathol (1989) 11:439–56. 10.1007/BF00201881 [DOI] [PubMed] [Google Scholar]
  • 29.Galvao-Castro B, Sa Ferreira JA, Marzochi KF, Marzochi MC, Coutinho SG, Lambert PH. Polyclonal B cell activation, circulating immune complexes and autoimmunity in human american visceral leishmaniasis. Clin Exp Immunol (1984) 56:58–66. [PMC free article] [PubMed] [Google Scholar]
  • 30.Lawley TJ, Peck GL, Moutsopoulos HM, Gratwohl AA, Deisseroth AB. Scleroderma, Sjogren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med (1977) 87:707–9. 10.7326/0003-4819-87-6-707 [DOI] [PubMed] [Google Scholar]
  • 31.Gratwohl AA, Moutsopoulos HM, Chused TM, Akizuki M, Wolf RO, Sweet JB, et al. Sjogren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med (1977) 87:703–6. 10.7326/0003-4819-87-6-703 [DOI] [PubMed] [Google Scholar]
  • 32.Tyndall A, Dazzi F. Chronic GVHD as an autoimmune disease. Best Pract Res Clin Haematol (2008) 21:281–9. 10.1016/j.beha.2008.03.003 [DOI] [PubMed] [Google Scholar]
  • 33.Rubtsova K, Rubtsov AV, Thurman JM, Mennona JM, Kappler JW, Marrack P. B cells expressing the transcription factor T-bet drive lupus-like autoimmunity. J Clin Invest (2017) 127:1392–404. 10.1172/JCI91250 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Rubtsova K, Rubtsov AV, Cancro MP, Marrack P. Age-associated B cells: a T-bet-dependent effector with roles in protective and pathogenic immunity. J Immunol (2015) 195:1933–7. 10.4049/jimmunol.1501209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Manoussakis MN, Tzioufas AG, Silis MP, Pange PJ, Goudevenos J, Moutsopoulos HM. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol (1987) 69:557–65. [PMC free article] [PubMed] [Google Scholar]
  • 36.Nagele EP, Han M, Acharya NK, DeMarshall C, Kosciuk MC, Nagele RG. Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One (2013) 8:e60726. 10.1371/journal.pone.0060726 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Moutsopoulos HM. Sjogren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol (1994) 72:162–5. 10.1006/clin.1994.1123 [DOI] [PubMed] [Google Scholar]
  • 38.Moutsopoulos HM. Sjogren’s syndrome: a forty-year scientific journey. J Autoimmun (2014) 51:1–9. 10.1016/j.jaut.2014.01.001 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES